Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?

Por Dirix, L. Y., Van Dam, P. A., Prove, A. M., Vermeulen, P. B.
Publicado em 2010

Current view on ductal carcinoma in situ and importance of the margin thresholds: A review

Por Van Cleef, A., Altintas, S., Huizing, M., Papadimitriou, K., Van Dam, P., Tjalma, W.
Publicado no Facts Views Vis Obgyn (2014)

Prognostic value of bcl-2 expression in patients with operable carcinoma of the uterine cervix.

Por Tjalma, W, Weyler, J, Goovaerts, G, De Pooter, C, Van Marck, E, van Dam, P
Publicado em 1997

Circulating tumour cells in the central and the peripheral venous compartment in patients with metastatic breast cancer

Por Peeters, D J E, Van den Eynden, G G, van Dam, P-J, Prové, A, Benoy, I H, van Dam, P A, Vermeulen, P B, Pauwels, P, Peeters, M, Van Laere, S J, Dirix, L Y
Publicado em 2011

Immunohistochemical study of topoisomerase II-alpha expression in primary ductal carcinoma of the breast.

Por Hellemans, P, van Dam, P A, Geyskens, M, van Oosterom, A T, Buytaert, P, Van Marck, E
Publicado em 1995

Prognostic value of bcl-2 expression in invasive breast cancer.

Por Hellemans, P., van Dam, P. A., Weyler, J., van Oosterom, A. T., Buytaert, P., Van Marck, E.
Publicado em 1995

The socio-economical impact of intravenous (IV) versus subcutaneous (SC) administration of trastuzumab: future prospectives

Por Papadmitriou, K., Trinh, X.B., Altintas, S., Van Dam, P.A., Huizing, M.T., Tjalma, W.A.A.
Publicado no Facts Views Vis Obgyn (2015)

Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes

Por Peeters, D J E, van Dam, P-J, Van den Eynden, G G M, Rutten, A, Wuyts, H, Pouillon, L, Peeters, M, Pauwels, P, Van Laere, S J, van Dam, P A, Vermeulen, P B, Dirix, L Y
Publicado em 2014

Tissue preparation for simultaneous flow cytometric quantitation of tumour associated antigens and DNA in solid tumours.

Por van Dam, P A, Watson, J V, Lowe, D G, Cox, H, Curling, M, Shepherd, J H
Publicado em 1990

Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype

Por Van der Auwera, I, Limame, R, van Dam, P, Vermeulen, P B, Dirix, L Y, Van Laere, S J
Publicado em 2010

Prognostic value of prostaglandin F2 alpha concentrations in breast carcinoma.

Por van Dam, P A, Vergote, I B, Laekeman, G M, Keersmaeckers, G H, Uyttenbroeck, F L, Herman, A G
Publicado em 1989

Quantification and prognostic relevance of angiogenic parameters in invasive cervical cancer.

Por Tjalma, W., Van Marck, E., Weyler, J., Dirix, L., Van Daele, A., Goovaerts, G., Albertyn, G., van Dam, P.
Publicado em 1998

A scoring system for immunohistochemical staining: consensus report of the task force for basic research of the EORTC-GCCG. European Organization for Research and Treatment of Canc...

Por van Diest, P J, van Dam, P, Henzen-Logmans, S C, Berns, E, van der Burg, M E, Green, J, Vergote, I
Publicado em 1997

Benchmarking and audit of breast units improves quality of care

Por van Dam, P.A., Verkinderen, L., Hauspy, J., Vermeulen, P., Dirix, L., Huizing, M., Altintas, S., Papadimitriou, K., Peeters, M., Tjalma, W.
Publicado em 2013

Real-time RT–PCR detection of disseminated tumour cells in bone marrow has superior prognostic significance in comparison with circulating tumour cells in patients with breast canc...

Por Benoy, I H, Elst, H, Philips, M, Wuyts, H, Van Dam, P, Scharpé, S, Van Marck, E, Vermeulen, P B, Dirix, L Y
Publicado em 2006

Plasma fibrin D-dimer levels correlate with tumour volume, progression rate and survival in patients with metastatic breast cancer

Por Dirix, L Y, Salgado, R, Weytjens, R, Colpaert, C, Benoy, I, Huget, P, van Dam, P, Prové, A, Lemmens, J, Vermeulen, P
Publicado em 2002

Higher TNF-α, IGF-1, and Leptin Levels are Found in Tasters than Non-Tasters

Por Wang, Rui, van Keeken, Nika M. A., Siddiqui, Sana, Dijksman, Lea M., Maudsley, Stuart, Derval, Diana, van Dam, P. Sytze, Martin, Bronwen
Publicado em 2014

Expression of c-erbB-2, c-myc, and c-ras oncoproteins, insulin-like growth factor receptor I, and epidermal growth factor receptor in ovarian carcinoma.

Por van Dam, P A, Vergote, I B, Lowe, D G, Watson, J V, van Damme, P, van der Auwera, J C, Shepherd, J H
Publicado em 1994

Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer using Affymetrix-based genome-wide gene-expression analysis

Por Van Laere, S, Van der Auwera, I, Van den Eynden, G, Van Hummelen, P, van Dam, P, Van Marck, E, Vermeulen, P B, Dirix, L
Publicado em 2007

NF-κB activation in inflammatory breast cancer is associated with oestrogen receptor downregulation, secondary to EGFR and/or ErbB2 overexpression and MAPK hyperactivation

Por Van Laere, S J, Van der Auwera, I, Van den Eynden, G G, van Dam, P, Van Marck, E A, Vermeulen, P B, Dirix, L Y
Publicado em 2007